Knowledge of the clinical and biological profile of patients infected with HIV
and hepatitis B and/or C is essential in order to identify and implement effective
management strategies. Methods : This was a retrospective descriptive
study from January 01, 2016 to June 01, 2021. Adult patients aged at least 18
years infected with HIV type 1 and/or 2, naïve to ARV treatment. Univariate
analyses were assessed using Pearson’s Chi2 test. The Student Newman test
was used for comparison between groups using R software version 4.0.2. Objective
: To draw up the epidemiological, clinical, paraclinical and evolutionary
profiles of HIV-treated-patients in relation to HIV/HBV and HIV/HCV
co-infections in order to allow the identification and the implementation of
effective management strategies. Results : Of the 379 patients included 280 (73.88%) were women. At treatment initiation, the mean age was 40.14 ±
11.84 years. The majority of patients consulted at WHO stage III (51.45%).
Clinical suspicion was the most frequent screening circumstance (51.71%).
The pathologies frequently reported at the first consultation were diarrhea
(28%) and shingles (16%). Body mass index was normal in 50.5% of patients.
HIV1 infection was the majority (91.03%). A total of 270 had a CD4 count at
treatment initiation. The mean CD4 cell count was 304.17 ± 242.06 cells/μL,
and 116 (42.59%) of them had a CD4 ≤ 200 cells/μL. Viral load at treatment
initiation was documented in 62 patients (16.35%) and 70.97% of them had a
detectable viral load (greater than 1000 copies/mL). The clinical and biological
evolution was relatively good in patients after therapeutic initiation.
HIV-HBV co-infection was 24.11% and HIV-HCV co-infection was 2.26%.
The mortality rate was 3.69%. Conclusion : These results reflect a significant
delay in HIV infection diagnosis. Furthermore, hepatitis B and/or C is
co-infections that increasingly affect people living with HIV. It also appears
that COVID 19 disease has had a strong impact on patient management.
Thus, new screening strategies must be implemented to encourage early diagnosis
of HIV, hepatitis B and C. Effective strategies are also necessary to
fight HIV in the context of epidemics and/or pandemics.

HIV Clinical-Biological Profile Hepatitis B and C Co-Infection